Guided by our patient-centered mission and science-driven strategy, Lustgarten supports flexibility, fearlessness, creative confidence, and a culture of innovation and dedication to scientific rigor. We are breaking down industry silos to drive collaboration and information sharing to advance pancreatic cancer research.
Collaborations Include:
Break Through Cancer
In 2022, Lustgarten Foundation partnered with Break Through Cancer to bring their Team Lab approach that maximizes interdisciplinary collaboration among researchers to pancreatic cancer. The Lustgarten Foundation has invested in two projects, Conquering KRAS and Demystifying Pancreatic Cancer, bringing teams of researchers from five of the nation’s top cancer research centers to boldly tackle two of the biggest challenges in cancer. The Conquering KRAS project is focused on developing effective combination therapy strategies to target KRAS – the driver, and potential Achilles heel, of more than 90% of pancreatic tumors. The Demystifying Pancreatic Cancer project will develop tools that will allow researchers to follow a tumor’s response to therapy during clinical trials – allowing us to understand what factors drive response and resistance to treatments.
INSPIRE
In partnership with the Cancer Research Institute (CRI), Lustgarten has created an initiative focused exclusively on supporting pancreatic cancer immunotherapy research. INSPIRE (Integrated Network for Supporting Pancreatic Cancer Immunotherapy Research Efforts) encompasses the established and ongoing adaptive platform trial, REVOLUTION, evaluating first-line chemo-immunotherapy treatment combinations for patients with metastatic pancreatic adenocarcinoma.
Pancreatic Cancer Collective
The Pancreatic Cancer Collective, funded by the Lustgarten Foundation and Stand Up To Cancer, accelerates research for pancreatic cancer patients who desperately need better treatments. Since 2012, Lustgarten Foundation and Stand Up To Cancer have built a robust and illustrious collaboration, jointly funding over 400 investigators across nearly 70 leading research centers in both the United States and the United Kingdom.
Other funding partnerships:
